Pancreatic cancer is a devastating disease, highly lethal that presents multiple challenges for genomic studies. The average survival rate at 5 years is 60 %. Tests and procedures to detect, diagnose and stage pancreatic cancer are performed at the same time so they have many complications for patients. The advances in the technology next-generation sequencing (NGS) have adapted to clinical oncology, identifying new mutations and rare cancers, allowing personalized medicine. A complete genomic analysis of the disease opens new therapeutic pathways becoming the hope of patients with poor prognosis.

Keywords: cancer, pancreas, next-generation sequencing, NGS.